Inclusion Criteria:  To be eligible to participate in this study, an individual must meet all of the following criteria:  Have a diagnosis of metastatic colorectal cancer previously treated with at least two lines of therapy for unresectable/metastatic disease Have microsatellite stable disease Adequate hematologic and end organ function  Exclusion Criteria:  An individual who meets any of the following criteria will be excluded from participation in this study:  Patients with known MSI-high status or known mismatch repair deficiency (dMMR) Patients in whom both mismatch repair and microsatellite stability status are unknown History of severe allergic, anaphylactic, or other hypersensitivity reactions to any of the study medications or their classes Left-sided (at or distal to the splenic flexure) RAS/BRAF wild-type metastatic colorectal cancer who are EGFR inhibitor naïve. Prior therapy with an anti-PD-1, anti-PD-L1, anti PD L2, anti-CD47, or anti-SIRPα agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX 40, CD137)